Stem-Cell Transplantation Ineffective for Double-Hit Lymphoma

Consolidative autologous SCT did not improve survival for patients in first remission after induction chemoimmunotherapy.

Patients with diffuse large B-cell lymphoma (DLBCL) carrying the chromosomal translocations CMYC plus BCL2 and/or BCL6 — so-called double-hit lymphoma (DHL) — have poor treatment outcomes versus most DLBCL patients, as well as a high risk for central nervous system (CNS) dissemination.

To assess the role of consolidative autologous stem-cell transplantation (ASCT) for DHL patients in first complete remission following induction rituximab (R)-chemotherapy, investigators conducted a retrospective analysis at 19 U.S. academic medical centers. Patients were assessed for relapse-free survival (RFS) and overall survival (OS) based on induction regimen and whether ASCT was performed. Of 159 patients, 62 received ASCT and 97 did not; those who did n…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Stem-Cell Transplantation Ineffective for Double-Hit Lymphoma

Topics

Reviewing Author